Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.41 |
| ▸ | PPARG | P37231 | 2/20 | 0.35 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 7/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2187666 | 0.82 | TGFBR1 (0.41) | TGFBR1PPARGS1PR4GRM2 | |
| SCHEMBL12506843 | 0.82 | TGFBR1 (0.43) | TGFBR1PPARGS1PR4GRM2SLC6A4 | |
| SCHEMBL2829829 | 0.78 | EGFR (0.44) | EGFRKDRPPARGSLC6A4HAO1 | |
| SCHEMBL21863802 | 0.76 | EGFR (0.43) | EGFRKDRPPARGSLC6A4 | |
| SCHEMBL2187112 | 0.76 | HTT (0.43) | TGFBR1S1PR4MEN1KMT2A | |
| SCHEMBL739388 | 0.75 | GRM2 (0.41) | S1PR4GRM2 | |
| SCHEMBL2787972 | 0.73 | TGFBR1 (0.35) | EGFRTGFBR1PPARGS1PR4SLC6A4 | |
| SCHEMBL2835404 | 0.73 | EGFR (0.40) | EGFRKDRSLC6A4MEN1KMT2A | |
| SCHEMBL3654965 | 0.72 | EGFR (0.45) | EGFRKDRPPARGGRM2SLC6A4 | |
| SCHEMBL16502358 | 0.71 | GRM2 (0.43) | TGFBR1S1PR4GRM2SLC6A4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748621-B2 | 1,3-disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones | Janssen Pharmaceuticals, Inc. (US) | 2014-06-10 | — | — | US | disclosed |
| US-8748621-B2 | 1,3-disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones | Janssen Pharmaceuticals, Inc. (US) | 2014-06-10 | — | — | US | disclosed |
| US-8748621-B2 | 1,3-disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones | Janssen Pharmaceuticals, Inc. (US) | 2014-06-10 | — | — | US | disclosed |
| US-20120309793-A1 | 1,3-DISUBSTITUTED 4-(ARYL-X-PHENYL)-1H-PYRIDIN-2-ONES | ADDEX PHARMA, S.A. (CH) | 2012-12-06 | — | — | US | disclosed |
| US-20120309793-A1 | 1,3-DISUBSTITUTED 4-(ARYL-X-PHENYL)-1H-PYRIDIN-2-ONES | ADDEX PHARMA, S.A. (CH) | 2012-12-06 | — | — | US | disclosed |
| US-20120309793-A1 | 1,3-DISUBSTITUTED 4-(ARYL-X-PHENYL)-1H-PYRIDIN-2-ONES | ADDEX PHARMA, S.A. (CH) | 2012-12-06 | — | — | US | disclosed |
| US-8252937-B2 | 1,3-disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones | Janssen Pharmaceuticals, Inc. (US) | 2012-08-28 | — | — | US | disclosed |
| US-8252937-B2 | 1,3-disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones | Janssen Pharmaceuticals, Inc. (US) | 2012-08-28 | — | — | US | disclosed |
| US-8252937-B2 | 1,3-disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones | Janssen Pharmaceuticals, Inc. (US) | 2012-08-28 | — | — | US | disclosed |
| CN-101848893-B | 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones | ADDEX PHARMACEUTICALS SA | 2012-06-06 | — | — | CN | disclosed |
| EP-2200985-B1 | 1,3-DISUBSTITUTED 4-(ARYL-X-PHENYL)-1H-PYRIDIN-2-ONES | ORTHO MCNEIL JANSSEN PHARM (US) | 2011-07-13 | — | — | EP | disclosed |
| US-20100286206-A1 | 1,3-DISUBSTITUTED 4-(ARYL-X-PHENYL)-1H-PYRIDIN-2-ONES | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | US | disclosed |
| US-20100286206-A1 | 1,3-DISUBSTITUTED 4-(ARYL-X-PHENYL)-1H-PYRIDIN-2-ONES | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | US | disclosed |
| US-20100286206-A1 | 1,3-DISUBSTITUTED 4-(ARYL-X-PHENYL)-1H-PYRIDIN-2-ONES | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | US | disclosed |
| EP-2200985-A1 | 1,3-DISUBSTITUTED 4-(ARYL-X-PHENYL)-1H-PYRIDIN-2-ONES | Ortho-McNeil-Janssen Pharmaceuticals, Inc. (US) | 2010-06-30 | — | — | EP | disclosed |
| WO-2009033702-A1 | 1,3-DISUBSTITUTED 4-(ARYL-X-PHENYL)-1H-PYRIDIN-2-ONES | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| WO-2009033702-A1 | 1,3-DISUBSTITUTED 4-(ARYL-X-PHENYL)-1H-PYRIDIN-2-ONES | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309793-A1 | 1,3-DISUBSTITUTED 4-(ARYL-X-PHENYL)-1H-PYRIDIN-2-ONES | GRM2, GRM1, GRM3 | EGFR 1448/4885KDR 2285/4885TGFBR1 585/4885 |
| US-20100286206-A1 | 1,3-DISUBSTITUTED 4-(ARYL-X-PHENYL)-1H-PYRIDIN-2-ONES | GRM2, GRM1, GRM3 | EGFR 1448/4885KDR 2285/4885TGFBR1 585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.